Men With LUTS May Stop Alpha-Blocker Treatment

A small, randomized study suggests that more than one-third of older men experiencing lower urinary tract symptoms (LUTS) could potentially stop alpha-blocker treatment due to little or no benefit derived from the medication. This finding indicates a significant portion of patients might be candidates for "deprescribing," a process of carefully withdrawing medication. The study involved men who had been on alpha-blockers for at least 6 months and were randomized to either continue their current treatment or attempt to discontinue the medication under medical supervision. The primary outcome measured was the change in LUTS symptoms over a 12-week period. Researchers observed that a substantial number of men in the deprescribing group maintained or improved their symptom control without the medication, while others experienced a return of symptoms and were subsequently restarted on alpha-blockers. This nuanced approach highlights the importance of individualized treatment plans and reassessment of medication necessity, even for commonly prescribed drugs. The study's implications point towards reducing polypharmacy and potential side effects associated with long-term alpha-blocker use in this demographic. Further research is warranted to identify specific patient characteristics that predict successful discontinuation and to refine deprescribing protocols for LUTS management. The findings were presented at the American Urological Association (AUA) annual meeting.